key: cord-0785002-13dvqi56 authors: Lim, Chew Theng; Tan, Kang Wei; Wu, Mary; Ulferts, Rachel; Armstrong, Lee A.; Ozono, Eiko; Drury, Lucy S.; Milligan, Jennifer C.; Zeisner, Theresa U.; Zeng, Jingkun; Weissmann, Florian; Canal, Berta; Bineva-Todd, Ganka; Howell, Michael; O’Reilly, Nicola; Beale, Rupert; Kulathu, Yogesh; Labib, Karim; Diffley, John F.X title: Identifying SARS-CoV-2 Antiviral Compounds by Screening for Small Molecule Inhibitors of Nsp3 Papain-like Protease date: 2021-04-08 journal: bioRxiv DOI: 10.1101/2021.04.07.438804 sha: e4c0690eadfc45f9d37fcc2ddd7171c80839b344 doc_id: 785002 cord_uid: 13dvqi56 The COVID-19 pandemic has emerged as the biggest life-threatening disease of this century. Whilst vaccination should provide a long-term solution, this is pitted against the constant threat of mutations in the virus rendering the current vaccines less effective. Consequently, small molecule antiviral agents would be extremely useful to complement the vaccination program. The causative agent of COVID-19 is a novel coronavirus, SARS-CoV-2, which encodes at least nine enzymatic activities that all have drug targeting potential. The papain-like protease (PLpro) contained in the nsp3 protein generates viral non-structural proteins from a polyprotein precursor, and cleaves ubiquitin and ISG protein conjugates. Here we describe the expression and purification of PLpro. We developed a protease assay that was used to screen a custom chemical library from which we identified Dihydrotanshinone I and Ro 08-2750 as compounds that inhibit PLpro in protease and isopeptidase assays and also inhibit viral replication in cell culture-based assays. safety and effectiveness [9] [10] [11] . However, the emergence of a new variant of SARS-CoV-2 in the UK in September 2020, has raised great concern since it is 70% more transmissible [12] . Additional variants arising across the world may render the existing vaccines less efficient. Given the uncertainty of the progression of the virus and the time frame needed to vaccinate the global community, it is crucial to search for drugs to provide treatment for COVID-19 patients. The genome of COVID-19 is arranged as shown in Figure 1A [4] . Once the virus has entered a cell, two open reading frames, ORF 1a and ORF 1ab are translated. ORF1ab is generated from an internal ribosomal frame shift. This produces polypeptides that are processed by two viral proteases to produce 16 nonstructural proteins (nsp) 1 to 16. The main protease is the 3C-like protease (3CLpro), corresponding to nsp5. 3CLpro cleaves in between each of the nsp 4-16 proteins. The second protease, Papain-like protease (PLpro), is contained in a small domain of the nsp3 protein; it cleaves after LXGG motifs between each of the remaining nsp1-3 [13] . Interestingly, PLpro is also a deubiquitylase (DUB) and a delSGylase, cleaving after the diglycine residues of ubiquitin (Ub) and the UBL protein ISG15 (interferon-induced gene 15), respectively, and thus has roles outside polyprotein cleavage [14, 15] . In this paper we describe our search for PLpro inhibitors. Nsp3 is the largest non-structural protein (1945 amino acids). It contains multiple domains which are arranged in the following order: ubiquitin-like (Ubl-1), acidic-domain (AC domain), ADP-ribose-1"-phosphatase (ADRP) /macro/x-domain, SARS unique Domain (SUD), Ubl-2, PLpro domain, nucleic acid-binding domain (NAB), marker domain (G2M), double-pass transmembrane domains (TM 1-2 and TM [3] [4] , and the Y domain (subdomains Y1-3) [14, 16] (Figure 1A ). For expression and purification, we selected the region from 1564-1878 amino acids that has been previously described to produce a truncated nsp3 which encompasses the Ubl-2 and PLpro main domains [4, 14] . We expressed PLpro in both bacterial and insect cell systems to determine which versions of the purified protein retained the most enzymatic activity. For bacterial expression, PLpro was tagged with either His-Sumo or His-TEV at its Nterminus. After protein pulldown from bacterial lysate, the His-Sumo and His-TEV affinity tags were removed by Ulp1 and TEV proteases respectively ( Figure 1B and Supplementary Figure S1A ). For expression in insect cells, the protein was tagged with Flag-His at the N-terminus and the tag remained on the final protein (Supplementary Figure 1SB) . The activities of all 3 proteins were compared as described below. We used a quenched Förster (fluorescence) resonance energy transfer (FRET) technique to monitor the protease activity [17] . 2-aminobenzoyl (Abz) and a nitro-L-tyrosine (Y-(3-NO2)R), were added to opposite ends of a small synthetic peptide that contained the cleavage sequence recognized by PLpro. This generates a fluorescence-quenching pair ( Figure 2A ) in which emission from Abz is absorbed by the neighbouring Y-(3-NO2)R; cleavage is detected as an increase in apparent emission from Abz at 420 nM. Two cleavage sequences were initially selected which corresponded to the ten amino acids between nsp1/2 and nsp2/3, designated Pro1 and Pro2, respectively. To test for cleavage of the substrates, bacterial His-TEV-PLpro was added to the substrate in the assay buffer. Over the 20 minutes of incubation, increasing fluorescence signal was observed for substrate Pro2 but not for Pro1 (Supplementary Figure S2A) . Consistent with this, it has been recently shown that full length nsp3 protein but not the isolated PLpro domain can cleave between nsp1/2 [18] . Although cleavage of Pro2 occurred, the rate was relatively slow making it less suitable for screening. We therefore designed a third substrate based on Pro2, called Pro3, which lengthened the recognition sequence peptide from 10 to 12 amino acids [19] (Figure 2A ). This modification resulted in a more rapid reaction (Supplementary Figure S2B) and Pro3 was, therefore, used as substrate in subsequent experiments. The bacterial His-TEV-PLpro (tag removed) was more active than insect cell Flag-His-PLpro at the same enzyme concentration ( Figure S2D ). The two bacterial expression proteins, His-TEV and His-Sumo-PLpro (tags removed) showed similar activity ( Figure S2C ). Since the His-Sumo PLpro is an intact protein with no extra amino acids (after tag removal) and also produced a higher yield after purification, this version of PLpro was used for all of the remaining experiments. By assaying PLpro cleavage activity across a wide range of substrate concentrations, we found that the Michaelis constant (Km) for PLpro was quite high (1854 µM) ( Figure 2B ). Cleavage increased over an hour at a variety of enzyme concentrations ( Figure 2C ). We chose 1.75 µM of enzyme and 20 µM of substrate to use in the high-throughput screen. The screen to identify small molecule inhibitors was performed using an existing custom library of over 5000 compounds aliquoted at 2 different concentrations,1.25 µM or 3.75 µM, in a total of 48 384-well plates. The plates were organised with columns 3-22 containing the compounds; the remaining columns were used for reaction controls including substrate only and substrate with enzyme but no drug ( Figure 3Aii ). The PLpro enzyme was pre-incubated with the drugs for 10 minutes, and then the reaction was initiated by the addition of substrate. The activity was recorded from 0 to 20 minutes with 3 minutes intervals between readings, this resulted in 7 timepoints which were then used to calculate the slope (Figure 3Ai ). We selected a total of 29 candidates from the plates using 3.75 µM drug concentration and a further 8 candidates were selected from the plates with 1.25 µM concentration ( Figure 3B ) that exhibited apparent inhibition greater than or equal to 25%; 4 of the drugs were overlapping in both concentrations. Amongst the hits, 22 out of 29 drugs from the high concentration plates and 1 drug from the low concentration plates were auto-fluorescent at 420 nm, and were excluded from our list. Three additional candidates were eliminated because the degree of inhibition was weak and the same drugs did not inhibit at higher concentration. This narrowed the final list down to 7 drugs (Table 1) . We wanted to exclude artifacts that might result from the fluorescent-based assay. For this reason we designed a gel-based PLpro protease assay ( Figure 4A and B). We constructed a new version of the PLpro substrate that had the 10 amino acids at the junction of nsp2-3 containing the cleavage site attached to GST at the Nterminus and MBP at its C-terminus, resulting in a 67 kDa peptide (Supplementary Figure S3A ). If PLpro mediated cleavage occurs, products of 25 kDa and 42 kDa will be generated which can easily be detected and visualized by SDS-PAGE (see One of the hits from the screen, Dihydrotanshinone I was previously shown to inhibit the PLpro from SARS-CoV-1 [20] . Two other tanshinone derivatives, Tanshinone IIA and Cryptotanshinone, were shown to be better inhibitors of this enzyme than Dihydrotanshinone I [20] . In separate studies, a non-covalent inhibitor, GRL-0617, has been reported to be effective against SARS-CoV-1/ -2 PLpro by different groups [21] [22] [23] . We, therefore, decided to include these drugs in our validation experiments. As shown in Figure 4C Figure 5F -H), consistent with the gel-based assay results. During this time we realised that PDK1/Akt/Flt Dual Pathway Inhibitor was also identified in several other screens being performed in the lab. We, therefore, considered it to likely to be nonspecific and we eliminated it from further consideration. We performed orthogonal assays using two different substrates of PLpro to test the inhibition of isopeptidase activity of PLpro by the small molecule inhibitors identified in the screen. When K48-linked triubiquitin (Ub3) is incubated with PLpro, it is efficiently cleaved to diubiquitin (Ub2) and monoubiquitin (Ub1) as the final products [18] . Similarly, pro-ISG15 is cleaved to ISG15. When PLpro is preincubated with 10 μM of beta-Lapachone or Dihydrotanshinone I, we observed potent inhibition of both K48-linked Ub3 and pro-ISG15 cleavage whereas moderate inhibition was observed for both Ro 08-2750 and the previously identified inhibitor of PLpro, GRL-0617, at these concentrations ( Figure 6 ). A potential 3CLpro inhibitor, shikonin, did not inhibit isopeptidase activity with either substrate. These experiments demonstrate the inhibitory effect of these small molecules across a spectrum of PLpro substrates. We next tested the ability of these compounds to inhibit viral growth in a cell culture-based assay where VERO E6 cells are infected with SARS-CoV-2. Two of the drugs, beta-Lapachone and Cdk4 Inhibitor III, were cytotoxic in the low micromolar range and were not pursued (Supplementary Figure S4A Since remdesivir is the one and only approved antiviral compound for COVID-19, we wanted to test whether any of the drugs we have found show any synergy with remdesivir (Supplementary Figure S5) . However, addition of 0.5 µM remdesivir, a concentration just below that required to inhibit viral growth, did not reduce the EC50 of any of our compounds ( Figure 7A -Cii). Dihydrotanshinone I, which emerged as the best overall hit from our screen, is a natural compound isolated from lipophilic fraction of Salvia miltiorrhiza, which has a long history in traditional Chinese medicine [24] . Several derivatives of Tanshinones were previously reported to be inhibitors for SARS-CoV-1 PLpro and to a lesser extent in 3CLpro [20, 24] . We have found that Dihydrotanshinone I is the best inhibitor of SARS-CoV-2 PLpro and did not inhibit 3CLpro. Although we, like other groups [23, 25, 26], used a truncated nsp3 protein including just the Ubl2 and PLpro domains, and there is evidence that cleavage by the full length nsp3 may have slightly different specificities [18] . The fact that Dihydrotanshinone I stops viral replication suggests that it is a good nsp3 PLpro inhibitor in cells. PLpro also recognizes and removes K48-linked polyubiquitin chains (Ub) and ISG15 from host cell target proteins. It is known that either ubiquitin or ISG15 are covalently bonded to target proteins during the cellular response to viral infection. The coding sequence of SARS-CoV-2 nsp3 1564-1878 amino acid (NCBI reference sequence NC_045512.2) was selected as previously reported [14] . The His-TEV bacterial sequence was codon optimized (Table S2 ) and cloned into plasmid pET11a at NdeI/BamHI sites (synthesised and cloned by GeneWiz) (Addgene ID 169192). The His-Sumo bacterial version was codon optimized and cloned into K27-Sumo (Addgene ID 169193) via NEBuilder HiFi DNA Assembly Cloning Kit (NEB). Vector template was amplified using primers oEcoli-C_48 and 49, PLpro sequence was amplified from His-TEV bacteria strain using primers oEcoli-C_51 and 52. His-TEV and His-Sumo constructs were introduced into T7 express lysY/I q E. coli cell (NEB) for expression. Cells were grown at 37°C to log phase to achieve OD 0.8. TLKGG//APTKV (nsp2/3 junction) was used as the substrate for gel-based assay. GST-tag and MBP-tag were attached to its N-and C-terminus respectively (Addgene Fluorescence was monitored at 2 minutes for 20 minutes with 3 minutes intervals giving a total of 7 readings. MATLAB was used to process data (more details in nsp13 paper in this issue) 0.5 µM of enzyme was pre-incubated with the selected inhibitor drugs for 10 minutes. 0.5 µM of gel-based assay substrates were added and incubated at RT for 5 hrs. The reactions were ran on 4-15% TGX gel (BioRad, Hercules, CA) and stained with Instant blue stain (Expedeon). Expression and purification of PLpro and the substrates K48-linked Ub3 and pro-ISG15 were as described previously [18] . SARS-CoV-2 production, infection and recombinant mAb production was done as described by Zeng, Weissmann, Bertolin et al. this series. All data in this paper can be found in FigShare (https://figshare.com/). Ribosomal frame-shift An interactive web-based dashboard to track COVID-19 in real time. The Lancet Infectious Diseases Pattern of early human-to-human transmission of Wuhan First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures A new coronavirus associated with human respiratory disease in China Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties. The Lancet Respiratory Medicine Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine South Africa, and the UK. The Lancet Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults New variant of SARS-CoV-2 in UK causes surge of COVID-19. The Lancet Respiratory Medicine Coronaviruses-Methods and protocols. Coronaviruses: Methods and Protocols X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papainlike proteases The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein tRNA dynamics on the ribosome during translation Characterization of protease activity of Nsp3 from SARS-CoV-2 and its inhibition by nanobodies. bioRxiv Protease 2 (PLP2) from Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV): Expression, Purification, Characterization, and Inhibition Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication We thank Anne Early and Agustina P. Bertolin for their assistance and High-Throughput Screening (HTS) for dispensing the compound libraries. Theresa U.